Evidence map›Paper›PMID 18566211›Full record

ArticleMolecular cancer therapeutics2008

alpha-Catenin overrides Src-dependent activation of beta-catenin oncogenic signaling.

Landon J Inge, Sigrid A Rajasekaran, Daniel Wolle, Sonali P Barwe, Sergey Ryazantsev, Charles M Ewing, William B Isaacs, Ayyappan K Rajasekaran

Open access · bronzeAbstract read
In one paragraph

Article in Molecular cancer therapeutics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. NFrontiers in oncology · 2021
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Landon J IngeNemours Center for Childhood Cancer Research, Alfred I. DuPont Hospital for Children, 1701 Rockland Road, Wilmington, DE 19803, USA.
Sigrid A Rajasekaran
Daniel Wolle
Sonali P Barwe
Sergey Ryazantsev
Charles M Ewing
William B Isaacs
Ayyappan K Rajasekaran
DuPont (United States) · USJohns Hopkins University · USAlfred I. duPont Hospital for Children · USUniversity of California, Los Angeles · US

Funding

Role of Beta Subunit of Sodium Pump in Cell AdhesionR01DK056216 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAJASEKARAN, AYYAPPAN K. · 2001 to 2009
$2.1M
Role of Soluble E-cadherin in Epithelial Cell SignalingF31GM068985 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI INGE, LANDON J · 2003 to 2006
$107k
NIDDK NIH HHS DK 56216NIDDK NIH HHS R01 DK056216NIGMS NIH HHS F31 GM068985NIGMS NIH HHS F31-GM068985
6 · The paper itself

Abstract

Loss of alpha-catenin is one of the characteristics of prostate cancer. The catenins (alpha and beta) associated with E-cadherin play a critical role in the regulation of cell-cell adhesion. Tyrosine phosphorylation of beta-catenin dissociates it from E-cadherin and facilitates its entry into the nucleus, where beta-catenin acts as a transcriptional activator inducing genes involved in cell proliferation. Thus, beta-catenin regulates cell-cell adhesion and cell proliferation. Mechanisms controlling the balance between these functions of beta-catenin invariably are altered in cancer. Although a wealth of information is available about beta-catenin deregulation during oncogenesis, much less is known about how or whether alpha-catenin regulates beta-catenin functions. In this study, we show that alpha-catenin acts as a switch regulating the cell-cell adhesion and proliferation functions of beta-catenin. In alpha-catenin-null prostate cancer cells, reexpression of alpha-catenin increased cell-cell adhesion and decreased beta-catenin transcriptional activity, cyclin D1 levels, and cell proliferation. Further, Src-mediated tyrosine phosphorylation of beta-catenin is a major mechanism for decreased beta-catenin interaction with E-cadherin in alpha-catenin-null cells. alpha-Catenin attenuated the effect of Src phosphorylation by increasing beta-catenin association with E-cadherin. We also show that alpha-catenin increases the sensitivity of prostate cancer cells to a Src inhibitor in suppressing cell proliferation. This study reveals for the first time that alpha-catenin is a key regulator of beta-catenin transcriptional activity and that the status of alpha-catenin expression in tumor tissues might have prognostic value for Src targeted therapy.

Indexed as

Signal Transductionalpha Cateninbeta CateninCell Line, TumorCell NucleusCell ProliferationCyclin D1Gene Expression Regulation, NeoplasticHumansIntercellular JunctionsMaleOncogene ProteinsPhosphorylationProto-Oncogene Proteins pp60(c-src)Transcription, Geneticalpha Cateninbeta CateninCyclin D1Oncogene ProteinsProto-Oncogene Proteins pp60(c-src)

Identifiers

PMID18566211
PMCPMC2527861
OpenAlexW2135306934

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.